Sarepta Therapeutics (Sarepta Therapeutics) Float Percentage Of Total Shares Outstanding : 95.80% (As of Apr. 25, 2024)

View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Sarepta Therapeutics's float shares is 89.92 Mil. Sarepta Therapeutics's total shares outstanding is 93.86 Mil. Sarepta Therapeutics's float percentage of total shares outstanding is 95.80%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Sarepta Therapeutics's Insider Ownership is 16.46%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Sarepta Therapeutics's Institutional Ownership is 59.42%.

Sarepta Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Sarepta Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	89.92	/	93.86
	=	95.80%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics (Sarepta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

AB3A:Germany AB3A:Germany S1RP34:Brazil

Address

215 First Street, Suite 415, Cambridge, MA, USA, 02142

Website

https://www.sarepta.com

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Executives

Richard Barry	director	285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram	director, officer: President & CEO	2525 DUPONT DR, IRVINE CA 92612
Michael Andrew Chambers	director	215 FIRST STREET, CAMBRIDGE MA 02142
Wigzell Hans Lennart Rudolf	director	OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Bilal Arif	officer: Chief Tech Ops Officer	215 FIRST STREET, CAMBRIDGE MA 02129
Stephen Mayo	director	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Kathryn Jean Boor	director	3736 S. MAIN STREET, MARION NY 14505
Louise Rodino-klapac	officer: Chief Scientific Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens	director	6701 KAISER DRIVE, FREMONT CA 94555
Ryan Edward Brown	officer: SVP, General Counsel	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Ian Michael Estepan	officer: Chief Financial Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Joseph Bratica	officer: Principal Financial Officer	215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton	officer: SVP, General Counsel	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin	director	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Sandesh Mahatme	officer: Senior Vice President, CFO	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901